© 2024 Ideastream Public Media

1375 Euclid Avenue, Cleveland, Ohio 44115
(216) 916-6100 | (877) 399-3307

WKSU is a public media service licensed to Kent State University and operated by Ideastream Public Media.
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

The State Of Care For Perinatal And Postpartum Depression

There's only one postpartum depression medication currently approved by the FDA. And while it's known to be extremely effective, access is limited.
There's only one postpartum depression medication currently approved by the FDA. And while it's known to be extremely effective, access is limited.

Nearly one in seven people who give birth experience postpartum depression.

Right now, there’s only one PPD medication, called brexanolone, currently approved by the FDA. While it’s known to be extremely effective, access is very limited.

But a revolution in treating perinatal and postpartum depression may be underway.

Earlier this summer, researchers published promising Phase 3 trial results of a new medication called zuranolone.

From Time:

We talk with experts about the current landscape of treatment for perinatal and postpartum depression and what FDA approval of zuranolone could mean.

Copyright 2021 WAMU 88.5

Kathryn Fink
Kathryn Fink is a producer with NPR's All Things Considered.